EMEA grants Mologen medicine status for their cell-based gene therapy

12.06.2006

Mologen AG announced that they obtained medicine status for their cell-based gene therapy against kidney cancer. This status was granted by Innovation Task Force (ITF), a committee of the European medicines evaluation agency, EMEA.

Others than their proprietary DNA molecules MIDGE and dSLIM, cells are not regarded as medicine, and therefore this notification is of utmost importance. It is a major step forward for further clinical development of this cancer therapy in Europe.

Weitere News aus dem Ressort Forschung & Entwicklung

Meistgelesene News

Weitere News von unseren anderen Portalen

Kampf gegen Krebs: Neueste Entwicklungen und Fortschritte